PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v9i6.13025ArticleResearch on the Expression and Clinical Significance of KLF4 and KLF5 in Breast Cancerhttps://artdesignp.com/journal/PAR/9/6/10.26689/par.v9i6.13025WangJie,LiCaoyue,ZhangJinku2025962025-12-12As members of the Kruppel-like transcription factor family, KLF4 and KLF5 play critical roles in the development and progression of breast cancer, yet their functions are complex. KLF4 exhibits a dual role: on one hand, it inhibits metastasis by suppressing epithelial-mesenchymal transition (EMT) and activating E-cadherin transcription; on the other hand, it can sustain tumor stem cell properties to promote progression. Its tumor-suppressive or tumor-promoting effects are highly dependent on the status of p21 and the cellular microenvironment. KLF5 is significantly overexpressed in basal-like breast cancer (BLBC) and triple-negative breast cancer (TNBC), promoting tumor proliferation and metastasis by regulating the cell cycle (inducing Cyclin D1 and inhibiting p27), maintaining stemness (activating Slug/Nanog), and forming a positive feedback loop with KLF5-XPO1. Clinical studies have demonstrated that overexpression of KLF4 is associated with poor prognosis in patients, while small-molecule inhibitors targeting KLF5 (such as mifepristone and CDK7/BRD4 inhibitors) can inhibit the growth of triple-negative breast cancer (TNBC). Both KLF4 and KLF5 influence breast cancer heterogeneity and treatment response by regulating key signaling pathways. Future research should further elucidate their environment-dependent mechanisms to develop precise targeting strategies.

Wei W, Zeng H, Zheng R, et al., 2020, Cancer Registration in China and Its Role in Cancer Prevention and Control. The Lancet Oncology, 21(7): e342–e349.

Cifuentes C, Oeste C, Fernández-Pisonero I, et al., 2024, Unmutated RRAS2 Emerges as a Key Oncogene in Postpartum-Associated Triple-Negative Breast Cancer. Molecular Cancer, 23(1): 142.

Li C, Wang W, Leung C, et al., 2024, The KDM5 Family as Therapeutic Targets in Breast Cancer: Pathogenesis, Therapeutic Opportunities, and Challenges. Molecular Cancer, 23(1): 109.

MacDonald I, Nixon N, Khan O, 2022, Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies. Current Oncology, 29(7): 4768–4778.

Camacho-Vanegas O, Till J, Miranda-Lorenzo I, et al., 2013, Shaking the Family Tree: Identification of Novel and Biologically Active Alternatively Spliced Isoforms Across the KLF Family of Transcription Factors. The FASEB Journal, 27(2): 432–436.

Niu R, Tang Y, Xi Y, et al., 2020, High Expression of Krüppel-Like Factor 7 Indicates Unfavorable Clinical Outcomes in Patients With Lung Adenocarcinoma. Journal of Surgical Research, 250: 216–223.

Gupta R, Malvi P, Parajuli K, et al., 2020, KLF7 Promotes Pancreatic Cancer Growth and Metastasis by Up-Regulating ISG Expression and Maintaining Golgi Complex Integrity. Proceedings of the National Academy of Sciences, 117(22): 12341–12351.

Yao J, Zhang H, Liu C, et al., 2020, miR-450b-3p Inhibited the Proliferation of Gastric Cancer by Regulating KLF7. Cancer Cell International, 20(1): 47.

Zou H, Chen H, Zhou Z, et al., 2019, ATXN3 Promotes Breast Cancer Metastasis by Deubiquitinating KLF4. Cancer Letters, 467: 19–28.

Wang J, Place RF, Huang V, et al., 2010, Prognostic Value and Function of KLF4 in Prostate Cancer: RNAa and Vector-Mediated Overexpression Identify KLF4 as an Inhibitor of Tumor Cell Growth and Migration. Cancer Research, 70(24): 10182–10191.

Ghaleb A, McConnell B, Nandan M, et al., 2007, Haploinsufficiency of Krüppel-Like Factor 4 Promotes Adenomatous Polyposis Coli–Dependent Intestinal Tumorigenesis. Cancer Research, 67(15): 7147–7154.

Huang CC, Liu Z, Li X, et al., 2005, KLF4 and PCNA Identify Stages of Tumor Initiation in a Conditional Model of Cutaneous Squamous Epithelial Neoplasia. Cancer Biology & Therapy, 4(12): 1401–1408.

Foster K, Liu Z, Nail C, et al., 2005, Induction of KLF4 in Basal Keratinocytes Blocks the Proliferation–Differentiation Switch and Initiates Squamous Epithelial Dysplasia. Oncogene, 24(9): 1491–1500.

Roeland B, Bernards R, Peeper D, 2005, The KLF4 Tumour Suppressor Is a Transcriptional Repressor of p53 That Acts as a Context-Dependent Oncogene. Nature Cell Biology, 7(11): 1074–1082.

Semenza G, 2023, Mechanisms Underlying the Specification and Self-Renewal of Breast Cancer Stem Cells Mediated by Hypoxia-Inducible Factor 1. Stem Cells Translational Medicine, 12(12): 783–790.

Yu F, Li J, Chen H, et al., 2011, Kruppel-Like Factor 4 (KLF4) Is Essential for the Maintenance of Breast Cancer Stem Cells, as Well as for Cell Migration and Invasion. Oncogene, 30(18): 2161–2172.

Nagata T, Shimada Y, Sekine S, et al., 2017, KLF4 and NANOG Serve as Prognostic Biomarkers for Triple-Negative Breast Cancer. Breast Cancer, 24(2): 326–335.

Tiwari N, Meyer-Schaller N, Arnold P, et al., 2013, Klf4 Acts as a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 (Mapk8). PLoS ONE, 8(2): e57329.

Wang B, Zhao M, Cui N, et al., 2015, Krüppel-Like Factor 4 Induces Apoptosis and Inhibits Tumorigenic Progression in SK-BR-3 Breast Cancer Cells. FEBS Open Bio, 5(1): 147–154.

Zou H, Chen H, Zhou Z, et al., 2019, ATXN3 Promotes Breast Cancer Metastasis by Deubiquitinating KLF4. Cancer Letters, 467: 19–28.

Ghaleb A, Yang V, 2017, Krüppel-Like Factor 4 (KLF4): What We Currently Know. Gene, 611: 27–37.

Foster K, Frost A, McKie-Bell P, et al., n.d., Increase in GKLF Messenger RNA and Protein Expression During the Progression of Breast Cancer. Cancer Research, 60(22): 6488–6495.

Rowland B, Peeper D, 2006, KLF4, p21, and Context-Dependent Opposing Forces in Cancer. Nature Reviews Cancer, 6(1): 11–23.

Zou H, Chen H, Zhou Z, et al., 2019, ATXN3 Promotes Breast Cancer Metastasis by Deubiquitinating KLF4. Cancer Letters, 467: 19–28.

Wahler J, So J, Cheng L, et al., 2015, Vitamin D Compounds Reduce Mammosphere Formation and Decrease Expression of Putative Stem Cell Markers in Breast Cancer. The Journal of Steroid Biochemistry and Molecular Biology, 148: 148–155.

Roberts M, Anstine L, Finke V, et al., 2020, KLF4 Defines the Efficacy of the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, in Triple-Negative Breast Cancer Cells by Repressing the EGFR Gene. Breast Cancer Research, 22(1): 66.

Yori J, Johnson E, Zhou G, et al., 2010, Krüppel-Like Factor 4 Inhibits Epithelial-to-Mesenchymal Transition Through Regulation of E-Cadherin Gene Expression. Journal of Biological Chemistry, 285(22): 16854–16863.

Tiwari N, Meyer-Schaller N, Arnold P, et al., 2013, Klf4 Is a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 (Mapk8). PLoS ONE, 8(2): e57329.

Chen C, Benjamin M, Sun X, et al., 2006, KLF5 Promotes Cell Proliferation and Tumorigenesis Through Gene Regulation in the TSU-Pr1 Human Bladder Cancer Cell Line. International Journal of Cancer, 118(6): 1346–1355.

Shi P, Liu W, Tala T, et al., 2017, Metformin Suppresses Triple-Negative Breast Cancer Stem Cells by Targeting KLF5 for Degradation. Cell Discovery, 3(1): 17010.

Xia H, Wang C, Chen W, et al., 2013, The Krüppel-Like Factor 5 Transcription Factor Promotes Transcription of the Microsomal Prostaglandin E2 Synthase 1 Gene in Breast Cancer. Journal of Biological Chemistry, 288(37): 26731–26740.

Tang Y, Liu R, Zhu J, et al., 2025, Positive Feedback Regulation Between KLF5 and XPO1 Promotes Cell Cycle Progression in Basal-Like Breast Cancer. Advanced Science, 12(16): 2412096.

Jiang D, Qiu T, Peng J, et al., 2022, YB-1 Is a Positive Regulator of the KLF5 Transcription Factor in Basal-Like Breast Cancer. Cell Death & Differentiation, 29(6): 1283–1295.

Liu R, Shi P, Nie Z, et al., 2016, Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-Regulating KLF5 Expression. Theranostics, 6(4): 533–544.

Chen C, Yang N, Zhang Y, et al., 2019, Inhibition of Super Enhancer Downregulates the Expression of KLF5 in Basal-Like Breast Cancers. International Journal of Biological Sciences, 15(8): 1733–1742.